Citations

Clear

16267 citation(s) found for "Yu, David".

Angiomatoid fibrous histiocytoma in a 25-year-old male
Mansfield, Aaron S. , Larson, Brenda, Stafford, Scott L., Shives, Thomas C., Haddock, Michael G. , Dingli, David , Mansfield, Aaron S , Dingli, David

Mayo Clinic

Rare Tumors | June 8, 2010 | Volume: 2 | Issue: 2 | Pages: 54-56

10.4081/rt.2010.e20 | PMID 21139823 Get It

Angiomatoid fibrous histiocytoma (AFH) is a rare disease that is often misdiagnosed initially. Patients can present with a clinical picture concerning for other diseases, and pathologic review is not always revealing. Molecular diagnostics are increasingly being utilized to detect gene fusions characteristic for AFH. Surgery remains the mainstay of management, and can effectively control local recurrences and metastases. Herein we describe a case report of a 25-year-old gentleman whose presentation was concerning for lymphoma. Subsequently we review of the relevant literature.
Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Ca
Morice, Marie-Claude, Feldman, Ted , Ståhle, Elisabeth , Colombo, Antonio , Mack, Michael J. , Holmes, David R. , Torracca, Lucia , Es, Gerrit-Anne van, Leadley, Katrin, Dawkins, Keith D., Mohr, Friedrich W., Serruys, Patrick W. , Kappetein, A. Pieter , Es, Gerrit‐Anne van

Mayo Clinic

Circulation | June 8, 2010 | Volume: 121 | Issue: 24 | Pages: 2645-2653

10.1161/circulationaha.109.899211 | PMID 20530001 Get It

Background— The prospective, multinational, randomized Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to assess the optimal revascularization strategy between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), for patients with left main (LM) and/or 3-vessel coronary disease. Methods and Results— This observational hypothesis-generating analysis reports the results of a prespecified powered subgroup of 705 randomized patients who had LM disease among the 1800 patients with de novo 3-vessel disease and/or LM disease randomized to PCI with paclitaxel-eluting stents or CABG in the SYNTAX trial. Major adverse cardiac and cerebrovascular event rates at 1 year in LM patients were similar for CABG and PCI (13.7% versus 15.8%; Δ2.1% [95% confidence interval −3.2% to 7.4%]; P =0.44). At 1 year, stroke was significantly higher in the CABG arm (2.7% versus 0.3%; Δ−2.4% [95% confidence interval −4.2% to −0.1%]; P =0.009]), whereas repeat revascularization was significantly higher in the PCI arm (6.5% versus 11.8%; Δ5.3% [95% confidence interval 1.0% to 9.6%]; P =0.02); there was no observed difference between groups for other end points. When patients were scored for anatomic complexity, those with higher baseline SYNTAX scores had significantly worse outcomes with PCI than did patients with low or intermediate SYNTAX scores; outcomes for patients with CABG did not correlate with baseline SYNTAX score, but baseline EuroSCORE significantly predicted outcomes for both treatments. Conclusions— Patients with LM disease who had revascularization with PCI had safety and efficacy outcomes comparable to CABG at 1 year; longer follow-up is required to determine whether these 2 revascularization strategies offer comparable medium-term outcomes in this group of complex patients. Clinical Trial Registration— http://www.clinicaltrials.gov. Unique identifier: NCT00114972.
Response to Letter Regarding Article, “Manuscript Preparation and Publication”
Holmes, David R. , Nishimura, Rick A., Simari, Robert D., Hodgson, Patricia

Mayo Clinic

Circulation | June 7, 2010 | Volume: 121 | Issue: 22 | Pages: No page available

10.1161/circulationaha.109.929125 Get It

Evidence-based guideline update: Determining brain death in adults
Varelas, Panayiotis N. , Gronseth, Gary , Greer, David M. , Wijdicks, Eelco F. M. , Greer, David Matthew

Mayo Clinic

Neurology | June 7, 2010 | Volume: 74 | Issue: 23 | Pages: 1911-1918

10.1212/wnl.0b013e3181e242a8 | PMID 20530327 Get It

Pessimistic explanatory style
Singh, Jasvinder A. , O’Byrne, Megan M., Colligan, Robert C., Lewallen, David G. , Singh, Jasvinder A

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | May 31, 2010 | Volume: 92-B | Issue: 6 | Pages: 799-806

10.1302/0301-620x.92b6.23114 | PMID 20513876 Get It

Seligman’s theory of causal attribution predicts that patients with a pessimistic explanatory style will have less favourable health outcomes. We identified 702 patients who had undergone 894 primary total knee replacements between 1993 and 2005, who responded to follow-up surveys at two (n = 783 knee replacements) and/or five years (n = 443 knee replacements) and had also completed the Minnesota Multiphasic Personality Inventory long before the joint replacement (median = 16.6 and 14.5 years for two- and five-year cohorts, respectively). Scores from the Minnesota Multiphasic Personality Inventory Optimism-Pessimism scale were used to categorise patients as pessimistic (t-score > 60) or non-pessimistic (t-score ≤ 60). Multivariate logistic regression models assessing the effect of pessimistic explanatory style on pain or improvement in knee function were adjusted for gender, age, distance from the place of treatment and depression score. Pessimists reported (a) significantly more moderate or severe pain at two years with odds ratio 2.21 (95% confidence interval (CI) 1.12 to 4.35; p = 0.02), but not at five years when the odds ratio was 1.21 (95% CI 0.51 to 2.83; p = 0.67); and (b) less improvement in knee function at two years when the odds ratio was 0.53 (95% CI 0.30 to 0.96; p = 0.04), but not at five years when the odds ratio was 1.26 (95% CI 0.57 to 2.77; p = 0.57). No significant associations with moderate or severe limitation of activity were seen at two or five years. We conclude that a pessimistic explanatory style is associated with worse pain and functional outcomes two years after total knee replacement.
Surgical Treatment of Extracranial Internal Carotid Artery Dissecting Aneurysms
Piepgras, David G., McCaffrey, Thomas V., Mokri, Bahram, Schievink, Wouter I.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 35 | Issue: 5 | Pages: 809-816

10.1227/00006123-199411000-00002 | PMID 7838327 Get It

Computed Tomography-based Stereotactic Third Ventriculostomy: Technical Note
Goerss, Stephan J., Kall, Bruce A., Kispert, David B., Kelly, Patrick J.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 18 | Issue: 6 | Pages: 791-794

10.1227/00006123-198606000-00021 | PMID 3526170 Get It

Abstract This report describes a computed tomography-based computer-assisted stereotactic technique for performing 3rd ventriculostomy. The procedure has been performed on seven patients with acquired obstructive hydrocephalus of various etiologies. None of these patients have yet required shunting. (18:791–794, 1986)
Phase III, Placebo-Controlled Trial of Three Doses of Citalopram for the Treatment of Hot Flashes: NCCTG Trial N05C9
Barton, Debra L. , LaVasseur, Beth, Sloan, Jeff A. , Stawis, Allen N., Flynn, Kathleen, Dyar, Missy, Johnson, David B., Atherton, Pamela J., Diekmann, Brent, Loprinzi, Charles L. , Atherton, Philip J. , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2010 | Volume: 28 | Issue: 20 | Pages: 3278-3283

10.1200/jco.2009.26.6379 | PMID 20498389 Get It

Purpose Up to 75% of women experience hot flashes, which can negatively impact quality of life. As hot flash physiology is not definitively understood, it cannot be assumed that effective agents represent class effects. Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief. Methods A randomized, double-blind trial evaluated citalopram at target doses of 10, 20, or 30 mg/d versus placebo for 6 weeks. Postmenopausal women with at least 14 bothersome hot flashes per week recorded hot flashes for 7 days before starting treatment and were then titrated to their target doses. The primary end point was the change from baseline to 6 weeks in hot flash score. Results Two hundred fifty-four women were randomly assigned onto this study. Data for hot flash scores and frequencies showed significant improvement in hot flashes with citalopram over placebo, with no significant differences among doses. Reductions in mean hot flash scores were 2.0 (23%), 7.0 (49%), 7.7 (50%), and 10.7 (55%) for placebo and 10, 20, and 30 mg of citalopram, respectively (P ≤ .002). Improvement in secondary outcomes, such as the Hot Flash Related Daily Interference Scale, was statistically superior in the 20-mg arm. Citalopram was well-tolerated, with no significant negative adverse effects. Conclusion Citalopram is an effective, well-tolerated agent in managing hot flashes. There does not appear to be a significant dose response above 10 mg/d, but broader helpful effects of the agent appear to be more evident at 20 mg/d.